CD20 re-emergence in a patient with diffuse large b-cell lymphoma who experienced a CD20-negative relapse after glofitamab treatment

Key Points

• The case highlights the phenomenon of CD20 re-emergence in a patient previously treated for CD20-negative relapse.
• Patient diagnosed with diffuse large B-cell lymphoma
• Treated with glofitamab despite initial CD20-negative state
• Monitored for changes in CD20 expression during and post-treatment
• The patient experienced a relapse characterized by re-emergence of CD20-positive cells
• Glofitamab therapy was initially effective but failed to prevent relapse
• Implications for future treatment include reassessment of CD20 status in relapsed cases.